Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Bausch + Lomb Corporation ( (BLCO) ).
Bausch + Lomb Corporation announced that it will release its second-quarter 2025 financial results on July 30, 2025, followed by a conference call and webcast to discuss the results and provide a business update. Additionally, the company will hold an investor day on November 13, 2025, to showcase its innovative product pipeline, indicating a focus on future growth and development in the eye health sector.
The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
Bausch + Lomb’s stock score of 62 reflects strong growth in certain segments and a stable balance sheet, but challenges remain in profitability and cash flow. The company’s proactive financial measures and positive analyst sentiment contribute positively, yet valuation and technical analysis indicate cautious optimism.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb is a global leader in eye health, offering a comprehensive portfolio of approximately 400 products including contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products, and ophthalmic surgical devices. Founded in 1853, the company has a significant global presence with around 13,500 employees and operations in about 100 countries. It is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey.
Average Trading Volume: 858,167
Technical Sentiment Signal: Sell
Current Market Cap: $4.38B
See more data about BLCO stock on TipRanks’ Stock Analysis page.